Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer

OBJECTIVE To evaluate a single cycle of adjuvant chemotherapy compared with longer duration chemotherapy for premenopausal women or chemoendocrine therapy for postmenopausal women with operable breast cancer using a quality-of-life-oriented end point, Q-TWiST (quality-adjusted analysis of TWiST: Time Without Symptoms and Toxicity). DESIGN Multicenter randomized clinical trial--International Breast Cancer Study Group (IBCSG: formerly Ludwig Group) Trial V. SETTING IBCSG participating centers in Sweden, Switzerland, Australia, Yugoslavia, Spain, New Zealand, Italy, Germany, and South Africa. PATIENTS Data were available for 1229 eligible patients with node-positive breast cancer who were randomized to receive one of three adjuvant treatments after at least a total mastectomy and axillary clearance. INTERVENTIONS Patients received either a single cycle of perioperative chemotherapy consisting of cyclophosphamide, methotrexate, fluorouracil, and leucovorin; or six cycles (6 months) of a conventionally timed chemotherapy consisting of cyclophosphamide, methotrexate, fluorouracil, and prednisone for premenopausal women or this combination plus tamoxifen for postmenopausal women; or both perioperative and conventionally timed chemotherapy for a 7-month course of adjuvant therapy. RESULTS At 5 years of median follow-up, patients who received the longer duration therapies had an improved 5-year disease-free survival percentage (53% compared with 36%; P less than 0.001) and 5-year overall survival percentage (73% compared with 63%; P = 0.001) compared with those who received the single perioperative cycle alone. By 3.5 years, the greater burden of toxic effects associated with the longer duration treatments was balanced by their superior control of disease. Within 5 years of follow-up, even after subtracting time with adjuvant treatment toxicity, patients gained an average of 2.2 months of Q-TWiST if treated with the longer duration therapies compared with the single cycle (P = 0.03). The gain for premenopausal patients was 2.8 months (P = 0.05), whereas the gain for postmenopausal women was 1.5 months (P greater than 0.2). CONCLUSIONS Six or seven months of adjuvant chemotherapy or chemoendocrine therapy improve both the quantity and quality of life for patients with node-positive breast cancer compared with a single short course of perioperative combination chemotherapy.

[1]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[2]  K. Pritchard Systemic adjuvant therapy for node-negative breast cancer: proven or premature? , 1989, Annals of internal medicine.

[3]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[4]  Richard D. Gelber,et al.  A quality-of-life-oriented endpoint for comparing therapies. , 1989 .

[5]  C. Redmond,et al.  Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  B Fisher,et al.  Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Gelber,et al.  A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G W Torrance,et al.  Utility approach to measuring health-related quality of life. , 1987, Journal of chronic diseases.

[10]  R. Gelber,et al.  Quality adjusted survival analysis. , 1990, Statistics in medicine.

[11]  R. Gelber,et al.  Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.